Age-specific survival in acute myeloid leukemia in the Nordic countries through a half century

. 2024 Mar 14 ; 14 (1) : 44. [epub] 20240314

Jazyk angličtina Země Spojené státy americké Médium electronic

Typ dokumentu dopisy, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid38480693
E-zdroje Online Plný text
Odkazy

PubMed 38480693
PubMed Central PMC10937905
DOI 10.1038/s41408-024-01033-7
PII: 10.1038/s41408-024-01033-7
Knihovny.cz E-zdroje

Zobrazit více v PubMed

Hemminki K, Hemminki J, Försti A, Sud A. Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment. Leukemia. 2023;37:854–63. doi: 10.1038/s41375-023-01852-w. PubMed DOI PMC

Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J. 2020;10:56. doi: 10.1038/s41408-020-0323-4. PubMed DOI PMC

Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77. doi: 10.1182/blood.2022016867. PubMed DOI

DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023;401:2073–86. doi: 10.1016/S0140-6736(23)00108-3. PubMed DOI

Kaplan ZLR, van Leeuwen N, Posthuma EFM, Visser O, Huls G, van de Loosdrecht AA, et al. Improved relative survival in older patients with acute myeloid leukemia over a 30-year period in the Netherlands: a long haul is needed to change nothing into something. Leukemia. 2022;36:596–8. doi: 10.1038/s41375-021-01503-y. PubMed DOI

Naur TMH, Jakobsen LH, Roug AS, El-Galaly TC, Marcher CW, Nørgaard JM, et al. Treatment intensity and survival trends among real-world elderly AML patients diagnosed in the period 2001-2016: a Danish nationwide cohort study. Leuk Lymphoma. 2021;62:2014–7. doi: 10.1080/10428194.2021.1893315. PubMed DOI

Juliusson G, Antunovic P, Derolf A, Lehmann S, Möllgård L, Stockelberg D, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113:4179–87. doi: 10.1182/blood-2008-07-172007. PubMed DOI

Juliusson G, Hagberg O, Lazarevic VL, Ölander E, Antunovic P, Cammenga J, et al. Improved survival of men 50 to 75 years old with acute myeloid leukemia over a 20-year period. Blood. 2019;134:1558–61. doi: 10.1182/blood.2019001728. PubMed DOI PMC

Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, et al. Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients. Am J Hematol. 2024;99:193–202. doi: 10.1002/ajh.27138. PubMed DOI

Larønningen SAG, Bray F, Engholm G, Ervik M, Guðmundsdóttir EM, Gulbrandsen J, et al. NORDCAN: cancer incidence, mortality, prevalence and survival in the Nordic countries, Version 9.3 (02.10.2023). 2023.

Hemminki K, Hemminki J, Försti A, Sud A. Survival trends in hematological malignancies in the Nordic countries through 50 years. Blood Cancer J. 2022;12:150. doi: 10.1038/s41408-022-00728-z. PubMed DOI PMC

Hjort Jakobsen L, Stidsholt Roug A, Kiesbye Øvlisen A, Werenberg Marcher C, Beier Ommen H, Theilgaard-Mönch K, et al. Temporal changes in survival among adult patients with acute myeloid leukaemia in the period 2000-2016: a Danish population-based study. Br J Haematol. 2021;193:482–7. doi: 10.1111/bjh.17213. PubMed DOI

Gjertsen BT. How to discover the exceptional venetoclax responders in AML/MDS? Br J Haematol. 2024;204:14–5. doi: 10.1111/bjh.19165. PubMed DOI

Derolf Å, Juliusson G, Benson L, Fløisand Y, Lazarevic V, Antunovic P, et al. Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor. Br J Haematol. 2020;188:187–91. doi: 10.1111/bjh.16265. PubMed DOI

Najít záznam

Citační ukazatele

Možnosti archivace